253 related articles for article (PubMed ID: 19830810)
1. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.
Marcias G; Erdmann E; Lapouge G; Siebert C; Barthélémy P; Duclos B; Bergerat JP; Céraline J; Kurtz JE
Hum Mutat; 2010 Jan; 31(1):74-80. PubMed ID: 19830810
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.
Tepper CG; Boucher DL; Ryan PE; Ma AH; Xia L; Lee LF; Pretlow TG; Kung HJ
Cancer Res; 2002 Nov; 62(22):6606-14. PubMed ID: 12438256
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
5. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
8. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
9. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
10. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor and invasion in prostate cancer.
Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor-mediated repression of novel target genes.
Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
Bergerat JP; Céraline J
Hum Mutat; 2009 Feb; 30(2):145-57. PubMed ID: 18800375
[TBL] [Abstract][Full Text] [Related]
14. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
15. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
Dehm SM; Schmidt LJ; Heemers HV; Vessella RL; Tindall DJ
Cancer Res; 2008 Jul; 68(13):5469-77. PubMed ID: 18593950
[TBL] [Abstract][Full Text] [Related]
16. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
17. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
19. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
